Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor

2015174 citationsJournal Articlebronze Open Access

Authors

Aili L. Lazaar · DE Technologies (United States)

Lucy Yang · Cambridge School

Rebecca Boardley · Age UK

Navin Goyal · DE Technologies (United States)

Jonathan Robertson · Age UK

Sandra Baldwin · Age UK

David E. Newby · University of Edinburgh

Abstract

GSK2256294 was well-tolerated and demonstrated sustained inhibition of sEH enzyme activity. These data support further investigation in patients with endothelial dysfunction or abnormal tissue repair, such as diabetes, wound healing or COPD.

Topics & Keywords

Eicosanoids and Hypertension Pharmacology Hormonal Regulation and Hypertension Alcohol Consumption and Health Effects

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: British Journal of Clinical Pharmacology

Volume 81, Issue 5, pp. 971-979

DOI: 10.1111/bcp.12855

Field-Weighted Citation Impact: 8.30